Financings
Grey Matters Closes First Tranche of $500,000 of its Private Placement Financing
Grey Matters Health Secures $500K Tranche as Florida Neuroimaging Clinics Edge Closer to Opening
Executive Summary
- Grey Matters Health Inc. closed the first tranche of its previously announced $1,000,000 non-brokered private placement on June 5, 2026.
- The tranche raised CAD $500,000 in gross proceeds through the issuance of 1,250,000 units at CAD $0.40 per unit.
- Company insiders contributed CAD $184,000 as a related party transaction, demonstrating minor internal confidence.
- Proceeds are allocated to advancing the Alzheimer’s Disease program, opening the first U.S. brain-specific neuroimaging clinic, covering general and administrative expenses, and funding working capital.
- The offering remains open for a second tranche of CAD $500,000, expected to close on or before June 30, 2026.
- This follows the April 22 announcement of the financing, the May 20 signing of a non-binding LOI with Catalyst MedTech for 200 brain PET scans, and the May 25 amendment to remove the warrant acceleration clause and extend the warrant term to three years.
Material Impact
- The closing of the first tranche is an expected execution of the April 22 financing announcement. The market was already aware of the dilutive offering priced at $0.40, which aligns with the depressed trading range.
- The removal of the warrant acceleration feature and the extension of the warrant term to three years (announced May 25) indicates management's willingness to soften terms to secure capital in a weak market environment. This reduces near-term dilution pressure but signals a lack of pricing power.
- Insider participation of $184,000 is a marginal positive signal but is not large enough to materially offset the dilution or change the risk profile.
- The news provides essential runway to reach the planned Q3/Q4 2026 clinic openings but does not alter the fundamental business trajectory, revenue generation timeline, or capital structure weakness.
- Impact is Routine - Positive. It is a necessary operational lifeline rather than a market-moving catalyst.
GREY · Price
Company Overview
- Grey Matters Health Inc. operates in the medical diagnostics sector, specializing in neuroimaging for Alzheimer’s disease, epilepsy, Parkinson’s, multiple sclerosis, and brain cancers.
- Flagship project: NovaScan Neuroimaging Clinics. The company is building a network of private U.S. clinics utilizing the FDA-cleared CareMiBrain system, a standalone brain PET scanner that reduces radiation exposure by 25% and operates in an upright, open environment to improve patient comfort.
- Business model: Dual revenue streams from direct physician referrals and large-scale Clinical Research Organization (CRO) services agreements.
- Current status: Pre-revenue, focused on clinic construction, regulatory compliance, and securing CRO contracts.
More from Grey Matters Health Inc.
May 25, 2026 · 07:00